Examkin

Question

Difficulty: MediumEnd-of-Life and Palliative Care

A 58-year-old woman with metastatic ovarian cancer is evaluated during a home hospice visit for a 4-day history of absent bowel movements and worsening lower abdominal discomfort. She has been taking escalating doses of oral morphine for severe pelvic pain over the past two weeks. Arrange the following steps in the correct chronological sequence for the evaluation and stepwise escalation of management for this patient's suspected opioid-induced constipation.

  1. 1Perform a targeted abdominal and rectal examination to exclude mechanical bowel obstruction.
  2. 2Initiate or optimize a scheduled stimulant laxative, such as senna.
  3. 3Incorporate an osmotic laxative, such as polyethylene glycol, into the daily regimen.
  4. 4Administer a peripherally acting mu-opioid receptor antagonist (PAMORA), such as methylnaltrexone.

Answer

The correct sequence is: 1) Perform an examination to rule out obstruction, 2) Initiate a scheduled stimulant laxative, 3) Add an osmotic laxative, and 4) Administer a peripherally acting mu-opioid receptor antagonist.
The correct sequence prioritizes patient safety by first excluding structural emergencies, followed by a stepwise escalation of pharmacological therapies based on mechanism of action. Mechanical obstruction must be ruled out before any laxatives are given. First-line medical therapy is a stimulant laxative to directly address the underlying opioid-induced hypomotility. If this fails, an osmotic laxative is added for a synergistic effect. Finally, targeted therapy with a PAMORA is reserved for refractory cases due to its specific indication and potential side effect profile.

Step-by-Step Solution

1
Evaluate for contraindications to laxative therapy.
Mechanical bowel obstruction and fecal impaction must be ruled out.
Administering laxatives in the presence of a complete obstruction can lead to severe pain, bowel ischemia, or perforation. This is especially important in patients with a history of intra-abdominal malignancies like ovarian cancer.
2
Initiate first-line pharmacological therapy.
Prescribe a scheduled stimulant laxative (e.g., senna).
Opioids primarily cause constipation by decreasing peristalsis via mu-receptors in the enteric nervous system; stimulant laxatives directly counteract this mechanism and serve as the foundation of therapy.
3
Escalate to combination laxative therapy.
Add an osmotic laxative (e.g., polyethylene glycol).
Dual therapy targeting both motility (stimulant) and stool consistency (osmotic) is the standard next step for persistent opioid-induced constipation.
4
Utilize targeted receptor antagonists for refractory cases.
Administer a PAMORA (e.g., methylnaltrexone).
PAMORAs block peripheral mu-receptors in the gastrointestinal tract without crossing the blood-brain barrier, treating refractory opioid-induced constipation without reversing central analgesia.

Key Concept

Stepwise management of opioid-induced constipation requires excluding mechanical obstruction first, followed by escalating therapy from stimulant laxatives, to combination therapy with osmotic laxatives, and finally to peripherally acting mu-opioid receptor antagonists (PAMORAs).
Estimated Time:1m 0s
Rate this question

Topics

End-of-Life and Palliative Care

More questions from this topic